Wird geladen...
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
Despite intensive multimodal therapy, the survival rate for high risk neuroblastoma (HR-NB) remains <50%. Most cases initially respond to treatment but almost half will subsequently relapse with aggressive treatment resistant disease. Novel treatments exploiting the molecular pathology of NB and/...
Gespeichert in:
| Veröffentlicht in: | Front Oncol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7145987/ https://ncbi.nlm.nih.gov/pubmed/32309213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00371 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|